Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Franklin Templeton

Putnam Small Cap Growth Fund Class R Shares (PSGRX)

Ticker PSGRX · · Holdings as of Jun 30, 2026

Expense ratio
1.36%$136/yr per $10k
5-yr return
+5.9%annualized
1-yr return
+8.6%as of Dec 2025
Net assets
$3.4Ball share classes
Holdings
110

Bottom line

Is PSGRX a good fund? The bottom line

PSGRX is the Class R share class of Putnam Small Cap Growth Fund, a managed small-cap mutual fund from Franklin Templeton.

Annual fees run 1.36% — about $136 a year on every $10,000 invested, more expensive than 80% of small-cap funds we track.

It returned +8.6% over one year, +5.9% a year over five years, +13.0% a year over ten (as of Dec 31, 2025, per its prospectus).

With $3.4 billion in net assets and 110 holdings, its largest position is Putnam Cash Collateral Pool LLC (11.0%) and the top 10 make up 30.6% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.36%)
  • 12b-1 marketing fee of 0.5% a year

Updated Nov 19, 2026

What PSGRX invests in

The fund seeks capital appreciation.

The fund invests mainly in common stocks of small U.S. companies, with a focus on growth stocks. Under normal circumstances, the fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity securities of growth companies of a size similar to those included in the Russell 2000 Index over the past six months. This policy may be changed only after 60 days notice to shareholders. The Investment Manager considers an issuer to be a growth company if (i) the issuer is included in an index which is representative of growth companies, (ii) the issuer is classified as a growth company by an independent third party, and/or (iii) the Investment Manager reasonably believes the issuer exhibits the characteristics of a growth company. When assessing growth companies, the Investment Manager considers a variety of factors, including but not limited…

From the fund's prospectus (filed Oct 26, 2026).

PSGRX performance

Average annual total returns
1 yr5 yr10 yr
PSGRX+8.6%+5.9%+13.0%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full PSGRX performance history →

What PSGRX costs

On a $10,000 investment, PSGRX's 1.36% expense ratio costs about $136 a year. The prospectus estimates $1,636 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full PSGRX fee table →

PSGRX top 10 holdings

#Holding% of fund
1Putnam Cash Collateral Pool LLC10.97%
2Putnam Short Term Investment Fund2.78%
3DigitalOcean Holdings, Inc.2.56%
4RBC Bearings, Inc.2.45%
5Nova Ltd.2.32%
6BrightSpring Health Services, Inc.2.07%
7Enova International, Inc.2.06%
8Advanced Energy Industries, Inc.2.02%
9Bel Fuse, Inc.1.70%
10Aritzia, Inc.1.68%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 30.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to PSGRX

More funds like PSGRX →

PSGRX FAQ

What is the expense ratio of PSGRX?
PSGRX's expense ratio is 1.36%, which works out to about $136 a year for every $10,000 invested. The prospectus estimates total costs of $1,636 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PSGRX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.36%); 12b-1 marketing fee of 0.5% a year. This is general information, not personalized advice.
What does PSGRX hold?
PSGRX's largest holdings are Putnam Cash Collateral Pool LLC (11.0%), Putnam Short Term Investment Fund (2.8%), DigitalOcean Holdings, Inc. (2.6%), RBC Bearings, Inc. (2.5%), Nova Ltd. (2.3%). It holds 110 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is PSGRX's 5-year return?
PSGRX returned +5.9% a year over the five years ending Dec 31, 2025, and +13.0% a year over ten years. Past performance does not guarantee future results.
Does PSGRX have a sales load?
No. PSGRX has no front-end sales charge.
Who manages PSGRX?
PSGRX is offered by Franklin Templeton through Putnam Funds Trust.